Guertin, Aetna senior vice president and CFO. ‘Operating income increased by nearly 46 % year over calendar year, from the addition of Coventry primarily. Coventry's businesses performed well, giving us increased confidence in our ability to achieve our synergy and accretion targets. ‘Our capital generation is strong, allowing us to execute upon our strategic vision and return cash to shareholders. This quarter we paid a dividend of $74 million and repurchased $333 million of shares. Year to time, Aetna has returned nearly $1.2 billion of capital to our shareholders through these two programs. Our budget, capital framework, and liquidity all continue to be very strong,’ stated Guertin. Total company results Operating earnings had been $561.8 million for the third quarter of 2013 compared with $523.2 million for the 3rd quarter of 2012.The total results suggest that BDLSCs could be purified and passaged. Related StoriesGlan Clwyd Medical center N Wales invest in Esaote's G-Scan MRI unit for weight-bearing scanningLoyola Medication, Palos Community Hospital jointly launch innovative telemedicine programFirst medical center installs Ortho Vision AnalyzerThe selecting culture system which has cholestatic serum may purify BDLSCs directly from bone marrow cells, which gives an easy technique to separate stem cells, by avoiding complicated immunological manipulation.